upper gi bleed n.
Skip this Video
Loading SlideShow in 5 Seconds..
UPPER GI BLEED PowerPoint Presentation
Download Presentation

Loading in 2 Seconds...

play fullscreen
1 / 49

UPPER GI BLEED - PowerPoint PPT Presentation

  • Uploaded on

UPPER GI BLEED. Presentation designed by Wendy Gerstein, MD Department of Medicine NMVAHCS. Objectives. Recognize bleeding and level of severity. Have a differential diagnosis for the bleeding. Know how to stabilize the patient and stop the bleeding. Decrease risk of future bleeding.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
    Presentation Transcript
    1. UPPER GI BLEED Presentation designed by Wendy Gerstein, MD Department of Medicine NMVAHCS

    2. Objectives • Recognize bleeding and level of severity. • Have a differential diagnosis for the bleeding. • Know how to stabilize the patient and stop the bleeding. • Decrease risk of future bleeding.

    3. Mr. J • HPI: Pt is a 43 yo male with h/o etoh abuse who presented with 3 day h/o vomiting blood (3-4x each day), about ½ cup each time. Pt fainted after vomiting on morning of admission, and friend brought him to the ER. No food or drink for last 2-3 days. Never happened before. Also with dark tarry stools x 2 days and sharp epigastric abdominal pain. • Pmhx: • Alcoholism, (6-30 beers/day x 25 years). • Low back pain secondary to military accident 1980. • Heart burn x 5 years – uses Tums.

    4. Meds: methocarbamol 750 mg po tid, etodolac 400mg po bid**. No known drug allergies • Shx: etoh, current tobacco, lives on Isleta Pueblo, partial disability. • PE: AF, p 80-86, bp 146/92, nl o2 sat • Exam remarkable for no jaundice or signs of liver disease **, nl abd exam. • Labs: wbc wnl, hct 37.3 with mcv 85, rdw 16.9, platelets 74. Bun 21, creat .8, potassium 2.9, chloride 99**. Liver enzymes – sgot 88, sgpt 70, Tbili 1.4 (direct .2). Inr 1.2 • CXR wnl

    5. In ER – nasogastric tube placed – removed 400 cc dark red liquid, lavaged to clear with 500cc of normal saline.

    6. Differential • Upper GI bleed: • Peptic ulcer disease (majority of cases) • Esophageal varices (14%) • Mallory-Weiss tear • Gastric erosions • Esophagitis/ulceration • Neoplasm • AVM malformations

    7. Epidemiology • 100 cases of UGI bleed per 100,000 adults. • Incidence increases with advancing age. • 150,000 hospitalizations per year in the US. • $2 billion per year in costs. • Mean length of stay 5.7 days. • Mortality ranges from 3.5%-7% (death usually from co-morbid conditions). • Bleeding stops spontaneously in 80%.

    8. TRIAGE

    9. Initial evaluation/management • Assess hemodynamic stability **. • Assess for active bleeding **. • 2 large bore IV’s, fluid resuscitation. • Tranfusion based on hct and co-morbidities. • Correct coagulopathies (FFP, platelets). • NGT lavage. • Evaluate need for airway protection.

    10. Notify GI consultants, surgeons if severe and acute. • Consider octreotide (somatostatin). • Endoscopy. • For complicated cases, can also use angiography, tagged rbc scan.

    11. Very low risk • Normal hemodynamics, no bleeding within last 48 hours, negative NGT aspirate (bilious w/ no blood)**, normal labs. • Outpatient evaluation acceptable. • Follow up within one week. • Oral PPI.

    12. Low risk • Hemodynamics return to normal within 1 hour of resuscitation. • No evidence of active bleeding **. • No active cardiopulmonary or liver disease. • No co-morbid conditions requiring hospitalization. • Immediate endoscopy with discharge from endoscopy suite.

    13. Moderate risk • Tachycardia continues despite resuscitation. • Requires more than 2 units PRBC’s. • Advanced age, cardiopulmonary disease, liver disease. • Admit to hospital bed. • Early EGD when patient stable.

    14. High risk • Active bleeding. • Persistent hypotension. • Severe co-morbidities. • Needs airway protection. • ICU admission. • Endoscopy when stable.

    15. Triage for Mr. J… • Actively bleeding, low hct, probable liver disease, vitals normal on admission (although h/o syncope). Where would you place him?

    16. He was admited to MICU, 2 peripheral IV’s secured, started on IV octreotide, IV pepcid, IVF’s, vitals and hct monitored. • GI performed EGD that afternoon: • No varices, large hiatal hernia, hemorrhagic gastritis in fundus. • They injected 3cc epinephrine, and then used cautery on lesions in fundus.

    17. Patient stared on IV protonix, switched to oral omeprazole 40 mg po bid next day. Hematocrit reached nadir of 29.5 (required no transfusions). Discharged with substance abuse follow up, and recommendations for repeat EGD in 3 months time.

    18. Endoscopy • Should be performed within 12 hours of admission. • Reduces rebleeding rates, number of surgeries, number of units transfused. • Mortality has not yet been shown to be reduced based on meta-analysis. • Non-thermal and thermal methods used for hemostasis.

    19. Complications of endoscopy include: • Aspiration • Hypotension/hypoventilation (due to sedation) • Perforation

    20. Octreotide • Long-acting analog of somatostatin. • Inhibits release of vasodilator hormones such as glucagon – indirectly causes splanchnic vasoconstriction which decreases portal inflow. • Has not yet been shown to have a clearly established benefit on mortality. • Used as infusion for up to 5 days in variceal bleeds.

    21. Acid suppression • Essential for preventing re-bleeding in the initial 72-hour period after index bleed. • HCL and pepsin in UGI tract appear to be antihemostatic. • Want to maintain intragastric pH at 7 or higher (pepsin destruction occurs at 8). • H2 blockers: block histamine H2 receptors on the parietal cell.

    22. Proton Pump Inhibitors: inhibit production of H+/K+ adenosine triphosphate (final step in acid production). • In high risk lesions, certain studies have shown that omeprazole significantly decreases risk of rebleeding. Another study showed omeprazole infusion after endoscopic treatment reduced risk of re-bleed, reduced length of stay, and transfusion requirements.

    23. Break point: continue for specific discussions on PUD, H. pylori, varices, and Mallory-Weiss tears, if time permits. • Otherwise skip to slide 45 for final slides.

    24. PUD (peptic ulcer disease) • Major causes include H. pylori, NSAID’s, stress, gastric acid (and various combinations). • Tobacco and alcohol can exacerbate existing lesions. • Initial symptoms can be vague – only 50% of patients with PUD present with typical symptoms, which include:

    25. - burning/gnawing pain - post-prandial pain 2-5 hours after eating. - relief with antiacids. - bloating, nausea, early satiety. • If ulcer is bleeding, typically presents with epigastric abdominal pain, hematemesis/coffee ground emesis, melena.

    26. Complications (other than bleeding) include obstruction, penetration (pancreas, duodenum) or perforation.

    27. H. pylori • No data to support routine testing in patients without ulcer disease. • Test patients with active or documented PUD or gastric MALT (biopsy urease test: 95% sensitive, 95% specific). • H. pylori infection doubles the risk of GI bleed in patients taking NSAID’s.

    28. One study from Hong Kong in 2002 showed that the prevalence of ulcers was significantly decreased in patients who had H. pylori eradicated (prior to starting NSAID’s). • Other tests for H. pylori: • Stool antigen (4 weeks post therapy). • Urease breath test. • H. pylori serum antibody.

    29. Treatment is with various combinations of a PPI and two antibiotics for 2 weeks. • Test for cure.

    30. Varices (gastric and esophageal) • Secondary to systemic or portal hypertension. • Associated with alcoholic liver disease and chronic active hepatitis (25-40% of patients with cirrhosis will have a variceal hemorrhage). • 30% mortality with each bleeding episode. • Risk of rebleed 60-70% in one year.

    31. Risks factors predictive of bleed: • Location (GE junction highest risk). • Size (diameter – related to Laplace’s law). • Appearance (red wale marks). • Clinical picture (Childs classification). • Variceal pressure (essentially 0% risk of bleeding over 12 months if pressure ≤ 13mmHg. 72% chance if >16mmHg).

    32. Acute therapy: band ligation and sclerotherapy. • Primary prophylaxis: • Propranolol (shown to reduce risk of hemorrhage at two years). • Variceal ligation (for high risk patients). • Secondary prophylaxis – TIPS procedure.

    33. Mallory-Weiss Tears • Longitudinal intramural dissection in distal esophagus/proximal stomach (submucosal artery bleed). • Usually associated with retching. • Described in 1929 by Mallory and Weiss in 15 alcoholic patients. • Predisposing conditions: • Hiatal hernia (seen in 40-100%)

    34. Chronic alcohol (40%-80%). • Amount of blood loss usually small and self-limited. • Heal within 24-48 hours. • Treat actively bleeding lesions with endoscopy. • PPI’s/H2 blockers promote healing.

    35. Key points • Triage and resuscitate patient quickly and appropriately. • Obtain quick endoscopy. • Test for H. pylori if ulcers present, and treat if positive. • Use PPI’s to reduce risk of rebleeding. • Remove medications that increase risk of bleeding.

    36. THE END

    37. Resources • www.uptodate.com • Lung E. “Evaluation and Management of Gastrointestinal bleeding Part 1: Nonvariceal Upper GI Bleeding.” Advanced Studies in Medicine. Vol 4 (4) April 2004. 186-190. • Papatheodoridis GV et al. “Effect of Helicobacter pylori infection on the risk of upper GI bleeding in users of NSAID’s.” Am J Med. 2004 May 1: 116(9) 601-5. • Exon DJ, Sydney Chung SC. “Endoscopic therapy for upper GI Bleed.” Best Pract Res Clin Gastroenterol. 2004 Feb; 18(1):77-98.